chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I began feeling bad during the day and running a fever on the evening of April 18. Over the next 3-4 weeks I continued to feel fatigued and run fevers, sometimes as high as 103 degrees. When I first got symptoms I got a covid test which came back negative. I went to the doctor and she also ran a covid test, which came back negative. She thought maybe it was sinuses and prescribed antibiotics. Those did nothing. After persistent fevers and feeling terrible, blood tests and sans were ordered. The scans showed my spleen was slightly enlarged showing that I was fighting off some type of infection. The blood work had some results that were outrageously our of the normal range they should be. I was finally sent to an infectious disease doctor and was diagnosed with CMV.
Patient took the first dose of oral typhoid vaccine and within 1.5 hours her eyes, nose, lips, and throat began to itch. Her lower lip also felt tingly. These symptoms lasted 4 hours.
Narrative:  59yo male patient died at home from cancer (melanoma primary with metastases to liver and lymph nodes. Pt died on 9/15/2021. Pt had received covid vaccines on 1/21/21 & on 2/23/21. Likely vaccines not related to pt's death given pt's terminal medical diagnosis & long length of time between vaccines and date of death.
Booster Moderna was administered 12/2, as I am on my menstruation cycle. I received a Janssen vaccination on 5/6/21. I have since had symptoms of arm sore/stiff-ness, fatigue, migraine, nausea, uterus and lower back pain, difficulty walking, and inability to think clearly at times. These symptoms are not normal during my usual menstruation cycle and were not present when I received my initial vaccination.
This case was reported by a nurse via call center representative and described the occurrence of extensive swelling of vaccinated limb in a 4-year-old male patient who received KINRIX (batch number 7559R, expiry date 14th October 2019). Concomitant products included ZYRTEC and PROQUAD. On 4th December 2017, the patient received KINRIX (intramuscular) .5 ml. On 6th December 2017, 2 days after receiving KINRIX and an unknown time after starting MOTRIN, the patient experienced injection site warmth (serious criteria other: as per reporter). On an unknown date, the patient experienced extensive swelling of vaccinated limb (serious criteria other: as per reporter), injection site pain (serious criteria other: as per reporter), injection site itching (serious criteria other: as per reporter), injection site cellulitis and papular rash. The patient was treated with MOTRIN. On an unknown date, the outcome of the extensive swelling of vaccinated limb, injection site pain, injection site itching, injection site cellulitis and papular rash were unknown and the outcome of the injection site warmth was not recovered/not resolved. It was unknown if the reporter considered the extensive swelling of vaccinated limb, injection site pain, injection site itching, injection site cellulitis and papular rash to be related to KINRIX. The reporter considered the injection site warmth to be probably related to KINRIX. Additional details were provided as follows: On 4th December 2017, the patient received PROQUAD in the left arm subcutaneously. At 13:00 hours, the patient received KINRIX in the right shoulder. The patient came back to the pediatrician's office 3 days after receiving the KINRIX vaccine due to a significant injection site reaction. The patient's family administered MOTRIN as an intervention. The nurse described the size of the reaction as  significant based on the size of the patient's arm (she compared it to the circumference of the bottom of a water bottle). They were most concerned about the warmness of it since they were concerned if it could be cellulitis or a reaction to the vaccine since warmness was not listed in the vaccine information statements (VIS). The reporter also mentioned that the patient had papules on the neck and forehead.
No additional AE's and no PQC's were reported.; A medical assistant reported that an improperly stored vaccine was administered to a patient.; This spontaneous report was received from a medical assistant concerning a patient of unknown age and gender. Information regarding the patient's medical history, concurrent conditions and concomitant medications was not reported.      On 11-APR-2022, the patient was vaccinated with an improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) for prophylaxis (lot number U008181 has been determined to be valid for varicella virus vaccine live (oka/merck), expiration date reported and established as 08-FEB-2023) (strength, dose, frequency, route of administration and anatomical location were not provided).         No adverse event reported.
nausea; vomiting; diarrhea; headaches,; pain in their arms at injection site,; sore throat; razor blades in my throat each time I swallowed; Initial information received on 30-Oct-2019 regarding an unsolicited valid non-serious case received from a consumer.  This case is linked to case 2019SA308609.  This case involves a 67 years old female patient who experienced sore throat (oropharyngeal pain), Nausea, vomiting, diarrhea (diarrhoea), headaches, (headache), pain in their arms at injection site (vaccination site pain) and razor blades in my throat each time swallowed (dysphagia), while she received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 28-Oct-2019, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot number and Expiry date unknown) via unknown route in unknown administration site.  On 28-Oct-2019, the patient developed a non-serious sore throat (oropharyngeal pain), Nausea, vomiting, diarrhea (diarrhoea), headaches, (headache), pain in their arms at injection site (vaccination site pain) and razor blades in my throat each time swallowed (dysphagia) 5 hours following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE.  (Other relevant tests included no lab data.) Final diagnosis was Swallowing difficult, pain in their arms at injection site, headaches, diarrhea, vomiting, nausea and Severe sore throat.  It was not reported if the patient received a corrective treatment.  On an unknown date, the event outcome is reported as Recovered for all the events.
Swollen lymph gland under arm of injection site, growing redness and warmth at injection site
Fever 102.5 off and on for 3 days.  Reported fevers with prior vaccines.
Information has been received from a physician concerning a 17 year old female who was vaccinated with Gardasil. Subsequently the patient fainted after being administered the vaccine. As of 16-MAR-2007 the patient was recovering. Additional information has been requested.
Slightly sore arm; This non-serious case was reported by a nurse and described the occurrence of pain in arm in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of cellulitis (1st dose received on May 2022 from lot number 42CM4 and expiry date 11th June 2023, refer linked case US2023AMR039736). Concurrent medical conditions included hypothyroidism, hypertension, anxiety, depression, migraine and allergic reaction to wasp sting (Yellow jacket allergy).   On an unknown date, the patient received the 2nd dose of Shingrix (intramuscular). On an unknown date, an unknown time after receiving Shingrix, the patient experienced pain in arm (Verbatim: Slightly sore arm). The outcome of the pain in arm was not reported.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.     It was unknown if the company considered the pain in arm to be related to Shingrix.   Linked case(s) involving the same patient:  US2023AMR039736   Additional Information: GSK Receipt Date: 11-APR-2023 The reporter reported that the patient received second dose and did not experienced any other issue other n a slightly sore arm. The reporter did consent to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2023AMR039736:Same reporter
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 70-year-old female patient who received SHINGRIX. Concurrent medical conditions included osteoarthritis, rheumatoid arthritis and sulfonamide allergy. Concomitant products included acyclovir, Levothyroxine, methotrexate and hydrocortisone. On 3rd May 2018, the patient received the 1st dose of SHINGRIX. On 4th May 2018, 1 days after receiving SHINGRIX, the patient experienced injection site pain and rash. On 5th May 2018, the patient experienced tiredness, memory impairment and feeling abnormal. SHINGRIX was discontinued. On 6th May 2018, the outcome of the injection site pain, tiredness, memory impairment and feeling abnormal were recovered/resolved. On an unknown date, the outcome of the rash was recovering/resolving. The reporter considered the injection site pain, rash, tiredness, memory impairment and feeling abnormal to be related to SHINGRIX. Additional details were provided as follows: The patient reported this case for herself. On the next day after vaccination, the patient noted soreness at site of injection and rash on her back, arm and down the side of her leg and groin area. One day after vaccination, the patient woke up and did not feel right in that she could not remember things and was very tired. The patient had lunch and went back to bed to rest. The patient also reported that, during her conversations with her husband, she had difficulty remembering things. On 6th May 2018, the patient was back to felt normal and that some of the rash still remained. The patient used hydrocortisone cream to treat the rash. The patient would not be getting the 2nd dose of SHINGRIX.
12/20/21 presented to ED with Fever, Weakness, and confusion and mild cough. Patient progressed to Acute hypoxic respiratory failure: Intubation on 12/27/2021 secondary to COVID-19 pneumonia. Treated MRSA and pseudomonas, Infectious disease and pulmonary service followed patient.  1/8/21 --- Patient continued to do poorly despite maximum ventilator support. Family called in to see patient and after discuss ion with intensivist, family decided compassionate extubating and comfort cares. Patient died at 12:21.
No adverse side effects from vaccine administration error. This is an error only report for expired vaccine given. Moderna was contacted in efforts to conclude if the vaccines administered on January 19th were efficacious or not "The vaccine administered on January 19, 2022 from lot number 077C21B maintained the activity necessary to protect against the SARS-CoV-2(COVID-19) virus at time of administration. "No known sequela from the event.
Patient felt light headed and fainted right after vaccine. Patient was helped to recovery position. She was conscious, alert and breathing normally when she was up. she regained consciousness immediately. pharmacist monitored patients pulse and blood pressure for over 30 minutes.it was normal ,Ems was called after 30 minutes since patient complained of not feeling well. Ems checked the patient and said her vitals were normal and she didn't have to go to the hospital. Patient was sent home after she felt better.
BILATERAL SWOLLEN LEGS; NUMBNESS ON LEFT ARM; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included: left hip replacement, right knee replacement, cardiac stent, and covid-19, and concurrent conditions included: non alcohol user, and non-smoker, and other pre-existing medical conditions included: The patient had no history of drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805025, expiry: 25-MAY-2021) dose was not reported, administered on 12-MAR-2021 for prophylactic vaccination. Concomitant medications included furosemide. On NOV-2020, Laboratory data included: COVID-19 antibody test (NR: not provided) not reported. On 12-MAR-2022, the patient experienced bilateral swollen legs, and numbness on left arm. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from bilateral swollen legs, and numbness on left arm. This report was non-serious.
Information has been received from a third party claims administrator for a pharmacy concerning a male patient (age not provided). On an unspecified date the patient was vaccinated with PNEUMOVAX 23 (lot # J009827, exp. date 10AUG2014). On 21DEC2013 the patient experienced an adverse reaction. The outcome of adverse reaction is unknown. Additional information has been requested.
This spontaneous report was received from a registered nurse referring to multiple, unspecified number of patients of unknown age and gender. Pertinent medical history, concurrent conditions and drug reactions/allergies were not reported. On unspecified dates, the patients were vaccinated with improperly stored doses of GARDASIL 9, lot # L007560 with expiration date 15-JUN-2017, (dose and route of administration were not provided). Concomitant medication was not reported. No adverse effects were reported. This is one of the several reports received from the same source. Additional information has been requested.
Headache and general soreness similar to first shot.  Swollen lymph node near left armpit (injection site arm)
Drainage from left nostril; Burning sensation in left nostril; Mild headache; Joint pain; Fever; patient called at day 36 from 1st dose and would like to know when she should receive her second injection; Tested positive for COVID; arm pain; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Tested positive for COVID), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient called at day 36 from 1st dose and would like to know when she should receive her second injection), RHINORRHOEA (Drainage from left nostril), NASAL DISCOMFORT (Burning sensation in left nostril) and PAIN IN EXTREMITY (arm pain) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm pain). On 07-Apr-2021, the patient experienced COVID-19 (Tested positive for COVID). On 15-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient called at day 36 from 1st dose and would like to know when she should receive her second injection). On an unknown date, the patient experienced RHINORRHOEA (Drainage from left nostril), NASAL DISCOMFORT (Burning sensation in left nostril), HEADACHE (Mild headache), ARTHRALGIA (Joint pain) and PYREXIA (Fever). At the time of the report, COVID-19 (Tested positive for COVID), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient called at day 36 from 1st dose and would like to know when she should receive her second injection), RHINORRHOEA (Drainage from left nostril), NASAL DISCOMFORT (Burning sensation in left nostril), PAIN IN EXTREMITY (arm pain), HEADACHE (Mild headache), ARTHRALGIA (Joint pain) and PYREXIA (Fever) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Apr-2021, SARS-CoV-1 test: positive Inconclusive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment information for the events was provided. Caller took 1st shot 10MAR2021. Was scheduled to receive second one on 09APR2021, but tested positive for COVID on 07APR2021. The side effects she experienced were mild headache, joint pain, and a burning sensation and drainage from her left nostril. These have been her COVID symptoms.. She has also been experiencing a fever.
Full-body hives starting two days after the Moderna booster. Hives have been present for three days straight now. They are raised, itchy, and full body (down arms, legs, back, stomach, etc.)
Received injection on 8/25/08. On the 26th on the (R) arm. Area red and warm to the touch.  Hard to the touch and the size of a 50 cent piece. No temperature.  Itchy.  Not red on 8/29, but still hard and a lump.
1. Extreme panic attacks currently persisting 24/7 after second Moderna Covid shot.  Xanax helps some but extremeness returns when it wears off. 2. Extreme migraine headaches started two weeks after first Moderna Covid shot.  Tapered down to low/moderate headache  until second shot a month later when extremeness returned.  Has tapered down to chronic (24/7) mild headache. 3. Moderate vertigo/dizziness persisting 24/7.  Body feels like it's moving on it's own. 4. Random heart palpitations, random high blood pressure.  Typically have low blood pressure due to genetics (so low at times I pass out, Cardiogenic Syncope).  5. Caffeine intake exasperates all the above in extreme manner.
not been functional; body was removed from her soul"; Sleepiness; Tiredness; Headache; Fever; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (not been functional), DISCOMFORT (body was removed from her soul"), SOMNOLENCE (Sleepiness), FATIGUE (Tiredness) and HEADACHE (Headache) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, the patient experienced ASTHENIA (not been functional), DISCOMFORT (body was removed from her soul"), SOMNOLENCE (Sleepiness), FATIGUE (Tiredness), HEADACHE (Headache) and PYREXIA (Fever). At the time of the report, ASTHENIA (not been functional), DISCOMFORT (body was removed from her soul"), SOMNOLENCE (Sleepiness), FATIGUE (Tiredness), HEADACHE (Headache) and PYREXIA (Fever) outcome was unknown.      No concomitant details were provided Treatment details include Advil, Tylenol   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Patient passed out (fainted) 2 minutes after GARDASIL shot I-dose. Patient was conscious, vitals were normal called 911 they checked patient's vitals and released patient to go home. Patient said she did not eat lunch, time was 3pm.
Fever, chills, body aches, headaches 1st day- two, then  sick on stomach and diarrhea the next couple days, then migraine? And I don?t usually get migraines.
felt Itchy all over the body; Rash all over the body; Itching Injection Site; Tender/Sore Injection Site; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (felt Itchy all over the body), RASH (Rash all over the body), VACCINATION SITE PRURITUS (Itching Injection Site) and VACCINATION SITE PAIN (Tender/Sore Injection Site) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (Itching Injection Site) and VACCINATION SITE PAIN (Tender/Sore Injection Site). On 11-Feb-2021, the patient experienced PRURITUS (felt Itchy all over the body) and RASH (Rash all over the body). On 11-Feb-2021, VACCINATION SITE PAIN (Tender/Sore Injection Site) outcome was unknown. At the time of the report, PRURITUS (felt Itchy all over the body), RASH (Rash all over the body) and VACCINATION SITE PRURITUS (Itching Injection Site) outcome was unknown.            No concomitants or treatment medications were reported.
5:42 PM Note    Telephone call with patient, she has been sick with intermittent fever, runny nose, back pain and leg pain for the past week.  Does not seem to be getting any better but also not getting any worse.  She has a procedure that is supposed to be done on 4/30.  Patient states that she did have her 2 Covid vaccinations and the last vaccination was 5 weeks ago.  She plans on canceling the procedure.   Care Coordination Progress Note RN (Registered Nurse)    COVID 19 Infusion Navigator Post Infusion Outreach #1   Infusion Date: 4/30/21    Medication ? bamlanivimab/etesevimab ? casirivimab ? bamlanivimab
Information has been received from a pharmacist who was vaccinated with MMR and reported that after 4 doses of the vaccine he still had not seroconverted. No further information is available.
Pt's symptoms began with a small localized rash and slowly progressed to a generalized rash covering entire body surface. Pt was prescribed Atarax and 2 days of bed rest. Follow-up report dated 5/4/00, states pt still has a scab-like rash remaining on thighs with a little itching and also tired. He missed 4 work days. Has not received any further Anthrax shots since the reported event.
she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal; she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal; she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL PAIN (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal), LIMB DISCOMFORT (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal) and DIARRHOEA (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Dec-2021, the patient experienced ABDOMINAL PAIN (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal), LIMB DISCOMFORT (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal) and DIARRHOEA (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal). At the time of the report, ABDOMINAL PAIN (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal), LIMB DISCOMFORT (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal) and DIARRHOEA (she had terrible abdominal pain an diarrhea, also some discomfort in the arm that was no big deal) outcome was unknown.            Patient stopped taking lupus and Ra medication before vaccination as recommended by her doctor. No treatment details were reported. Patient's DOB was reported as 10-Jul-2021.
After 7 days, large red blotch appeared at injection site and was very itchy.